BMS vs. Janssen: Who Will Claim the Crown in the Multiple Myeloma Treatment Market This Decade?
Multiple myeloma, a complex blood cancer stemming from malignant plasma cells in the bone marrow, presents unique challenges in treatment. With a growing understanding of this disease, the landscape of therapies has evolved significantly, with major players like Bristol Myers Squibb (BMS) and Janssen Pharmaceuticals at the forefront. This article explores the competitive dynamics between…